---
title: "Leerink Partners maintains Twist Bioscience at Outperform, lowers price target to $175 from $190"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305501201.md"
description: "Leerink Partners maintains a positive 'Outperform' rating on Twist Bioscience but lowers its price target from $190 to $175, reflecting a 7.9% decrease. This new target implies a 53.2% upside potential based on the November 12 closing price of $114.22. The adjustment aligns with recent analyst actions from firms like TD Cowen, Canaccord Genuity, and Baird, which have also maintained buy or outperform ratings with targets ranging between $135 and $150."
datetime: "2026-11-13T20:14:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305501201.md)
  - [en](https://longbridge.com/en/news/305501201.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305501201.md)
generator: "portal-rs"
---

# Leerink Partners maintains Twist Bioscience at Outperform, lowers price target to $175 from $190

Leerink Partners maintained Twist Bioscience at Outperform and lowered its price target to $175 from $190, a 7.9% decrease.

The price target implies an upside of 53.2% from the Nov 12 close of $114.22.

**Recent analyst actions on Twist Bioscience**

| Date   | Firm              | Action    | Rating     | Price target |
| ------ | ----------------- | --------- | ---------- | ------------ |
| Nov 13 | TD Cowen          | Maintains | Buy        | $137         |
| Nov 13 | Canaccord Genuity | Maintains | Buy        | $150         |
| Nov 13 | Baird             | Maintains | Outperform | $135         |

Across the three most recent analyst notes published on Twist Bioscience over the past 30 days, price targets range from $135 to $150.

Explore more price target data and ratings for Twist Bioscience on the , and track all previous and future analyst recommendations in the dedicated News Flow.

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TWST.US](https://longbridge.com/en/quote/TWST.US.md)

## Related News & Research

- [Twist Bioscience (TWST) Stock May Look Rich As Sales Face A High Bar](https://longbridge.com/en/news/305553660.md)
- [Is Twist Bioscience (TWST) Undervalued After Its New Oncology Research Product Launches?](https://longbridge.com/en/news/305175170.md)
- [Twist Bioscience Grants 17,681 Restricted Stock Units to 19 New Hires](https://longbridge.com/en/news/305169886.md)
- [Twist Bioscience Q4 revenue beats analyst expectations](https://longbridge.com/en/news/305313972.md)
- [Twist Bioscience (TWST) Could Be 17% Undervalued As New Product Launches Lift Attention](https://longbridge.com/en/news/304281250.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**